Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Mike Doustdar

CEOs are getting ruthless about worker performance

Corporate leaders are increasingly prioritizing results over employee comfort, with CEOs like Unilever's Fernando Fernandez demanding "volume growth, positive mix, consistent growth margin expansion." This shift towards "performance cultures" involves tougher accountability, potential layoffs, and a focus on tangible outcomes, signaling a departure from the more empathetic approach of the…

The Economic Times

Novo Nordisk A/S Q1 Earnings Call Highlights

Novo Nordisk A/S (NYSE:NVO) said its first quarter of 2026 was marked by rapid uptake of its newly launched Wegovy pill in the U.S., continued expansion of its obesity franchise and a series of pipeline and regulatory milestones, even as adjusted sales declined because of lower realized prices. Chi

Wegovy maker and OpenAI partnering to speed up search for new drugs

Wegovy maker and OpenAI partnering to speed up search for new drugs

The Danish drug manufacturer announced the partnership Tuesday, noting that the goal was to bring ‘new and better treatment options to patients faster’

The Independent UK

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Novo Nordisk joins forces with OpenAI to fast-track drug research

Danish pharma company Novo Nordisk has announced a partnership with OpenAI to apply artificial intelligence across its drug development process.

Label unhealthy foods, weight drug boss tells Australia

Workplace health checks, clearer labels on unhealthy foods and better education would help Australia reduce high rates of obesity, a drug company chief says.

Novo Nordisk and Hims & Hers Turn Patent Dispute Into Business Opportunity

Novo Nordisk drops its lawsuit against Hims & Hers as the companies partner to offer FDA-approved Wegovy and Ozempic through the telehealth platform.

International Business Times

Novo Nordisk announces plan to cut Ozempic and Wegovy prices up to 50 percent

One in eight Americans are taking weight loss drugs like Ozempic and Wegovy

The Independent UK

inkl

Read news from The Economist, FT, and more,
with one subscription

Novo Nordisk shares plunge on outlook warning as Mounjaro rival races ahead

Novo Nordisk shares plunge on outlook warning as Mounjaro rival races ahead

Wegovy and Ozempic maker Novo Nordisk forecast plunging sales and earnings in 2026, which saw the Danish drugmaker’s shares plummet by nearly a fifth.

Evening Standard

Wegovy and Ozempic maker forecasts sharp drop in revenue for 2026

Wegovy and Ozempic maker forecasts sharp drop in revenue for 2026

Novo Nordisk share price plunges after blaming lower US drug prices, patent protection issues and rising competition

The Guardian - UK

Novo Nordisk shares slide after Ozempic pill fails in Alzheimer’s trials

Novo Nordisk shares slide after Ozempic pill fails in Alzheimer’s trials

Report dashes hopes for new use for blockbuster weight-loss drug

The Guardian - UK

Novo Nordisk CEO's Bold Vow: Full Commitment to Weight-Loss Pill as Wegovy Price Falls

Novo Nordisk CEO's Bold Vow: Full Commitment to Weight-Loss Pill as Wegovy Price Falls

Novo Nordisk cuts Wegovy's price and commits fully to its upcoming weight-loss pill to stay competitive in the fast-growing obesity drug market.

International Business Times

Ozempic Maker Novo Nordisk Faces Board Shakeup

Ozempic Maker Novo Nordisk Faces Board Shakeup

On Friday, Novo Nordisk A/S' (NYSE:NVO) board director Mikael Dolsten said he will not seek election to the Board of Directors at the upcoming extraordinary general meeting on 14 November 2025.

Novo Nordisk Q3 2025 Earnings Call Transcript

Novo Nordisk Q3 2025 Earnings Call Transcript

Novo Nordisk A/S (NASDAQ:NVO) reported third-quarter financial results on Wednesday. The transcript from the company’s third-quarter earnings call has been provided below. NVO is having a challenging session. See if it is worth your attention here. This transcript is brought to you by Benzinga APIs. For real-time access to our entire…

Novo Nordisk cuts sales and profits guidance amid obesity drug competition

Novo Nordisk cuts sales and profits guidance amid obesity drug competition

The boss of the Wegovy firm linked its reduced guidance to the market for weight-loss treatments being ‘more competitive than ever’.

Evening Standard

Get all your
news in one place.

100's of premium titles.
One news app.

Ozempic Maker Novo Nordisk Trims Growth Outlook For Obesity Drugs

Novo Nordisk A/S (NYSE:NVO) on Wednesday reported third-quarter 2025 sales of roughly $11.75 billion (74.98 billion Danish kroner), slightly below the consensus of $11.88 billion.

The Guardian - UK

Ozempic maker struggles as it loses ground to rivals in weight-loss market

Novo Nordisk cuts sales and profit forecasts as it continues to lose ground to Mounjaro firm Eli Lilly

International Business Times

Ozempic-maker Novo Nordisk To Shake Up Board

Denmark's Novo Nordisk said Tuesday it would replace more than half of its board, including the chair, as the Ozempic and Wegovy maker restructures in the face of rising competition for its anti-obesity treatments.

Wegovy, Ozempic Maker Novo Nordisk Cuts Staff At Key US Production Sites

Novo Nordisk A/S (NYSE:NVO) has reportedly laid off dozens of employees at its largest U.S. manufacturing site in North Carolina, part of a global restructuring effort under new CEO Mike Doustdar.

Get all your
news in one place.

100's of premium titles.
One news app.

The Independent UK

Weight loss drugmaker to slash 9,000 jobs in £926 million cost cut

Novo Nordisk was at one point last year Europe's most valuable listed company

Novo Nordisk To Cut 9,000 Jobs As Competition From Eli Lilly Heats Up: Analyst Calls Move 'Tough, Natural...Very Necessary'

Novo Nordisk (NYSE:NVO) has announced a significant restructuring plan that will see the company cut 9,000 jobs, representing 11.5% of its workforce. The decision comes as the pharmaceutical giant faces mounting pressure from U.S. competitor Eli Lilly (NYSE:LLY).

The Guardian - UK

Wegovy maker Novo Nordisk to cut 9,000 jobs amid increased competition

Danish manufacturer of weight-loss and diabetes drugs under pressure from US rival Eli Lilly

The Guardian - UK

Trump reportedly asks EU to levy 100% tariffs on India and China; Ozempic maker Novo to cut 9,000 jobs – as it happened

US president wants to up pressure on Russia to end war in Ukraine

The Guardian - UK

Sales of Novo Nordisk’s diabetes drugs including Ozempic slow sharply

Danish company to cut costs and consider layoffs after competition from Mounjaro and the copycat market

1

People

189,749 stories

Mark Zuckerberg

Philipp Navratil

Fernando Fernandez

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

The Independent

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Artificial Intelligence

Parkinson Disease

Places

374,211 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play